TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Ventricular arrhythmia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade Ⅲ/Ⅳ neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of fecal shedding of polio vaccine virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: One or more episodes of rotavirus-associated diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Objective Response Rate (ORR) based on investigator's assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) based on IRC's assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Androxal Treated Subjects With Testosterone in the Normal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Subjects With 50% or Greater Decrease in Sperm Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cognitive aptitudes enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rescue analgesia use
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of weekly dosing requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oncological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gingival Margin Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean values of LAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Secondary Endovascular Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in VR-12 Mental Component Summary Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Meibomian gland expressibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radial and circumferential strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of the Influenza virus vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Time Needed to Correctly Insert the Arterial or Midline Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in SNOT-22 Symptomatic Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With at Least one Episode of Hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: latency to initiate ad-lib vaping session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of puffs purchased and consumed during the self-administration period
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: peak exercise oxygen consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24 hour urinary sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Motor lower limb improvement outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Note Errors (Related to Errors in Duration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Note Errors (Related to Errors in Loudness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale (HAMD) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Red Blood Cell/Plasma EPA Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in proteomic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in HRQoL of patients and their caregivers
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in HRQoL of patients aged >70 years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in HRQoL of patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in burden of patients' caregivers
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change from baseline of Alanine Aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change from baseline of Aspartate Aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change from baseline of Alkaline Phosphatase (ALP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Naming ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence of extra-NICE symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients diagnosed with lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concentration of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients with correct diagnosis of OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-hypopnea index measured with ApneaLink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea-hypopnea index measured during polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural angiographical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ocular Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Transfusion-independent Platelet Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for corticosteroids to control eyes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global assessment of ocular status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in performance rating scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Complete 2 Cycles of Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Participants Who Experience Therapeutic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful CTO recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time required for successful endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from major adverse limb related events below the knee
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Target Lesion Revascularization (TLR)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of treatment measured by participation rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of treatment on Client Satisfaction Questionnaire (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Palmar Gravimetric Sweat Production (GMSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Perioperative Death
Endpoint domain: Mortality/survival
Primary endpoint: Puncture duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with successful direct puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Purity of a visual intraoperative field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-procedural mortality or major morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Arteriovenous Fistula (AVF) Maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mass balance recovery of 14C as a cumulative percent of the radiolabeled dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach maximum (peak) concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Glutathione (GSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional assessment - Sit to Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Mobility - Time-up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular strength - Isokinetic Dynamometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRE-2 expression correlation with clinical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRE-2 expression correlation with pathological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in satiety hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Primary Tumor Response Rate at 4-6 Weeks Post Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Five-year Failure-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Five-Year Local Recurrence-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Five-Year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in number of teeth with dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Percentage of vaginal deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of patients with bacterioexcretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dynamics of chest radiograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamics of Intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All clinical and laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first detected AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective Response Rate (ORR) by irRC and RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Entrance Block Confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in rate pressure product at 0.1 mV ST-segment depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in degree of ST-segment depression at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure of Non-operative management
Endpoint domain: Adverse events/effects
Primary endpoint: sustained response to ITP treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe right upper quadrant or midline epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic Polypeptide (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of subjects experiencing DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Result of MTD
Endpoint domain: Adverse events/effects
Primary endpoint: Oral opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure algometry measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boceprevir AUC Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boceprevir Cmax Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Etravirine AUC Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of grade ≥ 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Isometric Quadriceps Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Clinical Response in the mITT Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinical Response in the CE Population
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response as measured by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BOLD response in prefrontal cortical regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Visual Acuity (Letters) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events associated with CAR T cell product infusions
Endpoint domain: Adverse events/effects
Primary endpoint: leukemia response to SCRI-CAR22v2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline Lipoproteins concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between planned and actual cup size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AML diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Residual GFR change at 1-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: compliance with directives
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to death of any cause (overall survival (OS))
Endpoint domain: Mortality/survival
Primary endpoint: Time to first progression of GBM (progression-free survival (PFS))
Endpoint domain: Mortality/survival
Primary endpoint: Changes in quality of life at month 2 and month 4 after start of TTFields treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Clinically Significant Abnormality in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Clinical Significant Abnormality in Laboratory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bacteria on hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Attending 6 Month Follow-up Appointment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: tube duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the curve (AUC) from time zero to last measurable concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Activity Performance assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Subjects Who Experience Any Major Adverse Event (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of Office Systolic Blood Pressure (OSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time required to complete suture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Definite Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve from dosing until 6 h after (AUC0-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Artificial Intelligent Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety observations
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Micturition-Related Urgency Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adherence to anti-hypertensive drug treatment at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to anti-hypertensive drug treatment at one month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to anti-hypertensive drug treatment at three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Shape Questionnaire (BSQ-8C) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thyroid disease prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Emergence Agitation (EA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of nebulized amikacin/fosfomycin via eFlow Nebulizer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of nebulized amikacin/fosfomycin via LC Sprint Nebulizer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of 24-h urinary free cortisol (UFC) excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Patients Achieving Baseline Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD signal in the medial prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV-1 DNA measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Glycemic Variability (mean amplitude of glycemic excursion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic Variability (Coefficient of Variation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic Variability (Standard Deviation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients finishing the study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: incidence of new caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unprotected anal intercourse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of anginal attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viability of ex vivo expended Allogeneic Natural killer cells (MG4101)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Purity of ex vivo expended Allogeneic Natural killer cells (MG4101)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kaplan-Meier Percentage of Participants Who Remained Alive or Had Valve Explanted Due to Anatomical Growth
Endpoint domain: Mortality/survival
Primary endpoint: Peak Gradient as Assessed by Echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Gradient as Assessed by Echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in lipoprotein particles size and number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in inflammatory and coagulation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CAD Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Remineralization potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic Augmentation Index - Time-Weighted Average 0-24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in systolic blood pressure > 30mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bradycardia with heart rate below 40 beats per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Digit span
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Category Fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroop Effect Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in hemagglutinin antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Tumor Necrosis Factor-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in High Sensitivity C-reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Lipopolysaccharide Binding Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes